Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
gene therapy
life sciences
martin shkreli
2
×
novartis
2
×
zolgensma
10x genomics
abbvie
allergan
amgen
anemia
antibiotic
astrazeneca
autism
autism spectrum disorder
avexis
biogen
bioinnovation capital
biolabs
boston
boston top stories
boulder/denver blog main
boulder/denver top stories
brian kaspar
bristol-myers squibb
cadent therapeutics
celgene
centers for disease control and prevention
chemotherapy
chinook therapeutics
clinical trials
clostridium difficile
community-acquired bacterial pneumonia
dana hilt
daprodustat
daraprim
david chacko
david marek
detroit blog main
What
biotech
2
×
august
bio
busy
days
decisions
devices
driving
drug
drugs
fda
good
healthcare
history
improved
industry
innovation
innovations
investment
legacy
life
long
medical
news
nods
opioid
outcomes
past
pricing
proud
public
regulatory
roundup
sarepta’s
sciences
seven
shkreli’s
slow
stumble
suits
Language
unset
Current search:
novartis
×
biotech
×
" martin shkreli "
×
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More